ClinicalTrials.gg
RecruitingNCT06138678VAiTUpdated Nov 25, 2024

VGR Accelerated TMS Treatment for Depression

An interventional study of iTBS (intermittent theta-burst stimulation) in Depression, sponsored by Vastra Gotaland Region. Recruiting at 2 sites in Sweden. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-11-25.

Sponsored by Vastra Gotaland Region · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jan 2024; still recruiting 2 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
146
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 183 studies in Depression with a site in Sweden — 34 open to participants now, 47 under way, 1 of them phase 3. Depression · Sweden.

Planned enrollment
62nd of 156
146 · median 113
Started
2024
with 19 others
No phase
124 of 183
24 open now
Primary completion
2027-01
later than 32 of 46 live
Registered
142nd of 183
by date
Lead sponsor
6 of 183
Vastra Gotaland Region

Among the 183 studies in Depression with a site in Sweden, this one is the 62nd largest by planned enrollment of the 156 interventional ones that give a count, is one of 20 that started in 2024, is one of 124 with no phase, reaches primary completion later than 32 of the 46 other live ones, and was the 142nd registered.

Depression

8,608 studies on the registry are indexed under Depression; 1,736 are open to participants now.

Browse Depression studies →

Open to participants now

34 of the 183 studies in Depression with a site in Sweden are open now. Recruiting first, the newest first:

28 more — sign in →

All 34 open studies →

A study can be open while its sites in Sweden have not opened yet or have stopped. Only those recruiting at a site in Sweden →

Who these studies take

Of the 1,098 Depression studies recruiting now, 475 (43%) set no upper age limit and 522 (48%) stop at 75 or younger; 205 take children under 18; 315 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 183 studies in Depression with a site in Sweden, or all of them as a file.
02

Study summary

Intermittent theta burst stimulation (iTBS), a variant of repetitive transcranial magnetic stimulation (rTMS), is a well documented method for treatment of depression.

The aim of the study is to assess the effect of an accelerated iTBS protocol compared to a routine iTBS protocol. In the accelerated protocol patients will receive 1200 pulses per session (2 sessions per day, 15 treatment days) and in the routine protocol patients will receive 600 pulses per session (1 session per day, 30 treatment days).

Participants (n = 146) will be recruited among patients referred to iTBS and randomized to treatment. Participants will be assessed by a psychiatrist, or a resident psychiatrist, prior to treatment to assure that they fulfill all inclusion criteria and non of the exclusion criteria. A psychiatrist, or a resident psychiatrist, will assess depressive symptoms 3 and 6 weeks after first day of treatment. Patients will complete self-rating questionnaires during screening, weekly for 6 weeks starting from the first day of treatment, and 6 months after end of treatment.

03

Conditions studied

  • Depression

Browse trials for

Keywords

  • iTBS
  • rTMS
  • Depression
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • diagnosis of depression verified through a Mini International Neuropsychiatric Interview (M.I.N.I.)
  • MADRS-S >= 20
  • unchanged medication last month
  • unchanged psychological treatment last month
  • admitted to psychiatric ward last month
  • no ECT or TMS last six months
  • provision of signed form
  • indication for TMS is depression

Exclusion criteria

Exclusion Criteria:

  • addiction (illicit drugs or alcohol)
  • pregnancy
  • epilepsy
  • conductive ferromagnetic or other metals implanted in the head or within 30 cm of the treatment coil
  • implanted device that is activated or controlled in any way by physiological signals
  • implanted mediation pumps
  • intracardiac lines, even when removed
  • regular use of benzodiazepines
  • any condition that seriously increases the risk of non-compliance or loss of follow-up
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
146 participants (estimated)

Study arms

  • Experimental
    Accelerated iTBS protocol

    Magnetic pulses of 120% of visual motor threshold applied in triplets of 50 Hz bursts, repeated at 5 Hz; 2 seconds on and 8 seconds off; 1200 pulses per session; total duration of 6 min 40 s over the left DLPFC (F3), given in 2 sessions per day (50 min interval) on 15 week days.

    Device: iTBS (intermittent theta-burst stimulation)

  • Active comparator
    Routine iTBS protocol

    Magnetic pulses of 120% of visual motor threshold applied in triplets of 50 Hz bursts, repeated at 5 Hz; 2 seconds on and 8 seconds off; 600 pulses per session; total duration of 3 min 20 s over the left DLPFC (F3), given in 1 session per day on 30 week days.

    Device: iTBS (intermittent theta-burst stimulation)

Interventions

  • DeviceiTBS (intermittent theta-burst stimulation)

    The iTBS treatment is a type of rTMS (repetitive transcranial magnetic stimulation), delivered with MagPro R30 stimulator and a conventional cool-B65 coil. The iTBS treatment is applied to over the dorsolateral prefrontal cortex using a standardized measuring of the anatomical landmark F3 from the 10-20 positioning system. The coil is positioned with the handle at in a 45 degree angle from the midline. The centre of the butterfly is placed towards the patient head.

06

What researchers measure

Primary outcomes

  1. Difference in MADRS-S from baseline to three weeks after first iTBS treatment

    The self-rating version of the Montgomery-Asberg Depression Rating Scale (MADRS-S) is a rating scale (0-54 points), where a higher score indicates worse depressive symptoms

    Time frame: 3 weeks

Secondary outcomes

  1. Difference in MADRS-S from baseline to one week after first iTBS treatment

    The self-rating version of the Montgomery-Asberg Depression Rating Scale (MADRS-S) is a rating scale (0-54 points), where a higher score indicates worse depressive symptoms

    Time frame: 1 week

  2. Difference in MADRS-S from baseline to two weeks after first iTBS treatment

    The self-rating version of the Montgomery-Asberg Depression Rating Scale (MADRS-S) is a rating scale (0-54 points), where a higher score indicates worse depressive symptoms

    Time frame: 2 weeks

  3. Difference in MADRS-S from baseline to four weeks after first iTBS treatment

    The self-rating version of the Montgomery-Asberg Depression Rating Scale (MADRS-S) is a rating scale (0-54 points), where a higher score indicates worse depressive symptoms

    Time frame: 4 weeks

  4. Difference in MADRS-S from baseline to five weeks after first iTBS treatment

    The self-rating version of the Montgomery-Asberg Depression Rating Scale (MADRS-S) is a rating scale (0-54 points), where a higher score indicates worse depressive symptoms

    Time frame: 5 weeks

  5. Difference in MADRS-S from baseline to six weeks after first iTBS treatment

    The self-rating version of the Montgomery-Asberg Depression Rating Scale (MADRS-S) is a rating scale (0-54 points), where a higher score indicates worse depressive symptoms

    Time frame: 6 weeks

  6. Difference in MADRS-S from baseline to six months after last iTBS treatment

    The self-rating version of the Montgomery-Asberg Depression Rating Scale (MADRS-S) is a rating scale (0-54 points), where a higher score indicates worse depressive symptoms

    Time frame: 6 months

  7. Difference in QIDS-SR from baseline to one week after first iTBS treatment

    The self-rating Quick Inventory of Depressive Symptomatology (QIDS-SR) is a rating scale (0-27 points), where a higher score indicates worse depressive symptoms

    Time frame: 1 week

  8. Difference in QIDS-SR from baseline to two weeks after first iTBS treatment

    The self-rating Quick Inventory of Depressive Symptomatology (QIDS-SR) is a rating scale (0-27 points), where a higher score indicates worse depressive symptoms

    Time frame: 2 weeks

  9. Difference in QIDS-SR from baseline to three weeks after first iTBS treatment

    The self-rating Quick Inventory of Depressive Symptomatology (QIDS-SR) is a rating scale (0-27 points), where a higher score indicates worse depressive symptoms

    Time frame: 3 weeks

  10. Difference in QIDS-SR from baseline to four weeks after first iTBS treatment

    The self-rating Quick Inventory of Depressive Symptomatology (QIDS-SR) is a rating scale (0-27 points), where a higher score indicates worse depressive symptoms

    Time frame: 4 weeks

  11. Difference in QIDS-SR from baseline to five weeks after first iTBS treatment

    The self-rating Quick Inventory of Depressive Symptomatology (QIDS-SR) is a rating scale (0-27 points), where a higher score indicates worse depressive symptoms

    Time frame: 5 weeks

  12. Difference in QIDS-SR from baseline to six weeks after first iTBS treatment

    The self-rating Quick Inventory of Depressive Symptomatology (QIDS-SR) is a rating scale (0-27 points), where a higher score indicates worse depressive symptoms

    Time frame: 6 weeks

  13. Difference in QIDS-SR from baseline to six months after first iTBS treatment

    The self-rating Quick Inventory of Depressive Symptomatology (QIDS-SR) is a rating scale (0-27 points), where a higher score indicates worse depressive symptoms

    Time frame: 6 months

  14. Difference in SDS from baseline to six weeks after first iTBS treatment

    The Sheehan Disability Scale (SDS) is a self-rating assessment (0-30 points), where a higher score indicates more pronounced functional impairment

    Time frame: 6 weeks

  15. Difference in SDS from baseline to six months after first iTBS treatment

    The Sheehan Disability Scale (SDS) is a self-rating assessment (0-30 points), where a higher score indicates more pronounced functional impairment

    Time frame: 6 months

  16. Difference in EQ-VAS from baseline to three weeks after first iTBS treatment

    The EQ-5D visual analogue scale (EQ-VAS) is a self-rating assessment (VAS 0-100 points), where a higher (VAS) score indicates a higher health-related quality of life

    Time frame: 3 weeks

  17. Difference in EQ-VAS from baseline to six weeks after first iTBS treatment

    The EQ-5D visual analogue scale (EQ-VAS) is a self-rating assessment (VAS 0-100 points), where a higher (VAS) score indicates a higher health-related quality of life

    Time frame: 6 weeks

  18. Difference in EQ-VAS from baseline to six months after first iTBS treatment

    The EQ-5D visual analogue scale (EQ-VAS) is a self-rating assessment (VAS 0-100 points), where a higher (VAS) score indicates a higher health-related quality of life

    Time frame: 6 months

  19. Difference in CGI-S from baseline to three weeks after first iTBS treatment

    The Clinical Global Impression - Severity scale (CGI-S) is a clinical rating scale (0-7 points), where a higher score indicates more severe symptoms

    Time frame: 3 weeks

  20. Difference in CGI-S from baseline to six weeks after first iTBS treatment

    The Clinical Global Impression - Severity scale (CGI-S) is a clinical rating scale (0-7 points), where a higher score indicates more severe symptoms

    Time frame: 6 weeks

  21. Difference in CGI-I from baseline to three weeks after first iTBS treatment

    The Clinical Global Impression - Improvement scale (CGI-I) is a clinical rating scale (0-7 points) of symptom improvement (lower score)/worsening (higher score) compared to baseline

    Time frame: 3 weeks

  22. Difference in CGI-I from baseline to six weeks after first iTBS treatment

    The Clinical Global Impression - Improvement scale (CGI-I) is a clinical rating scale (0-7 points) of symptom improvement (lower score)/worsening (higher score) compared to baseline

    Time frame: 6 weeks

  23. Number of patients in remission three weeks after first iTBS treatment

    A patient with a MADRS-S score of \< 10 is considered to be in remission

    Time frame: 3 weeks

  24. Number of patients in remission six weeks after first iTBS treatment

    A patient with a MADRS-S score of \< 10 is considered to be in remission

    Time frame: 6 weeks

07

Study locations

2 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2024 (actual). Primary completion is estimated for Jan 2027, 35 months after the start.

Of 3,486 non-industry interventional studies with no phase under Depression, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's planned 35 months is above that.

Counting every sponsor, half of 3,584 studies reached it within 21 months; a quarter within 9 and three quarters within 41.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 27, 2023
First posted
Nov 18, 2023
StartActual
Jan 15, 2024
Primary completionEst.
Jan 1, 2027
CompletionEst.
Aug 1, 2027
Last update
Nov 25, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 25, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06138678
Collaborators
Göteborg University, Uppsala University, The Swedish Society of Medicine
Responsible party
Sponsor
First posted
Nov 18, 2023
Start date
Jan 15, 2024
Primary completion
Jan 1, 2027 (estimated)
Completion
Aug 1, 2027 (estimated)
Last update
Nov 25, 2024

Study contacts

Melker Hagsäter, MD, MSc, PhD
Contact
melker.hagsater@vgregion.se
+46 3039 8000
Melker Hagsäter, MD, MSc, PhD
principal investigator · Västra Götaland Regional Council

Oversight

FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion